Knight Therapeutics (Knight Therapeutics) EV-to-Revenue : 1.49 (As of May. 07, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Knight Therapeutics's enterprise value is $363.5 Mil. Knight Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $243.6 Mil. Therefore, Knight Therapeutics's EV-to-Revenue for today is 1.49.

The historical rank and industry rank for Knight Therapeutics's EV-to-Revenue or its related term are showing as below:

KHTRF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.08 Med: 33.08 Max: 820.36
Current: 1.51

During the past 11 years, the highest EV-to-Revenue of Knight Therapeutics was 820.36. The lowest was 1.08. And the median was 33.08.

KHTRF's EV-to-Revenue is ranked better than
67.97% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.37 vs KHTRF: 1.51

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-07), Knight Therapeutics's stock price is $4.26. Knight Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.26. Therefore, Knight Therapeutics's PS Ratio for today is 1.88.

Knight Therapeutics EV-to-Revenue Historical Data

The historical data trend for Knight Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics EV-to-Revenue Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

16.10

1.71

2.06

1.59

1.29

Knight Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.59	1.23	1.36	1.10	1.29

Competitive Comparison of Knight Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's EV-to-Revenue falls into.

Knight Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Knight Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	363.516	/	243.571
	=	1.49

Knight Therapeutics's current Enterprise Value is $363.5 Mil.
Knight Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $243.6 Mil.

Knight Therapeutics (OTCPK:KHTRF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Knight Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	4.26	/	2.262
	=	1.88

Knight Therapeutics's share price for today is $4.26.
Knight Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.26.

Knight Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics (Knight Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (OTCPK:KHTRF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

GUD:Canada

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.